Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future

被引：0
|
作者：
Calegari, M. A. [1 ]
Orlandi, A. [1 ]
Cocomazzi, A. [2 ]
Martini, M. [2 ]
Bagala, C. [1 ]
Indellicati, G. [1 ]
Zurlo, V. [1 ]
Monterisi, S. [1 ]
Di Dio, C. [1 ]
Barile, R. [1 ]
Di Salvatore, M. A. [1 ]
Basso, M. [1 ]
Cassano, A. [1 ]
Larocca, L. M. [2 ]
Barone, C. [3 ]
机构：
[1] Univ Cattolica Sacro Cuore, Oncol Med, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Anat Patol, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Med Oncol, I-00168 Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.164
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-164
引用
收藏
页数：1
相关论文
共 50 条
  • [41] EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment
    Su, M.
    Chen, L.
    Hitre, E.
    Lee, W.
    Bai, L.
    Papai, Z.
    Kang, S.
    Dvorkin, M.
    Lee, M.
    Ludovic, E.
    Choi, H.
    Oh, S.
    Bodoky, G.
    Artru, P.
    Hwang, J.
    Bazin, I.
    Bosc, F.
    Bachet, J.
    Horvath, Z.
    Chang, C.
    Lin, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 23 - 23
  • [42] hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
    Wang, Wei
    Yu, Xinzhe
    Li, Hengchao
    Yang, Chuanxin
    Jin, Chen
    Huang, Xinyu
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [43] hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer
    Hale, J.
    Evans, A.
    Aughton, K.
    Elander, N. O.
    Ghaneh, P.
    Neoptolemos, J. P.
    Jackson, R.
    Cox, T. F.
    Campbell, F.
    Halloran, C. M.
    Mackey, J. R.
    Scarfe, A. G.
    Valle, J. W.
    Carter, R.
    Cunningham, D.
    Tebbutt, N. C.
    Goldstein, D.
    Shannon, J.
    Glimelius, B.
    Deakin, M.
    Charnley, R. M.
    Anthoney, A.
    Lerch, M. M.
    Mayerle, J.
    Costello, E.
    Palmer, D. H.
    Buechler, M. W.
    Greenhalf, W.
    PANCREAS, 2019, 48 (10) : 1436 - 1437
  • [44] Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment
    Poplin, Elizabeth
    Wasan, Harpreet
    Rolfe, Lindsey
    Raponi, Mitch
    Ikdahl, Tone
    Bondarenko, Ihor
    Davidenko, Irina
    Bondar, Volodymyr
    Garin, August
    Boeck, Stefan Hubert
    Heinemann, Volker
    Bassi, Claudio
    Evans, T. R. Jeffry
    Voong, Cynthia
    Kaur, Paramjit
    Isaacson, Jeffrey D.
    Allen, Andrew R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Prognostic Role of hENT1 and RRM1 in Patients with Advanced Pleural Mesothelioma Treated with Second Line Gemcitabine Based Regimens
    Cardona, Andres
    Arrieta, Oscar
    Rojas, Leonardo
    Corrales, Luis
    Wills, Beatriz
    Oblitas, George
    Bacon, Ludwing
    Martin, Claudio
    Cuello, Mauricio
    Mas, Luis
    Vargas, Carlos
    Carranza, Hernan
    Otero, Jorge
    Perez, Maria
    Gonzalez, Lisde
    Chirinos, Luis
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1366 - S1367
  • [46] hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
    Wei Wang
    Xinzhe Yu
    Hengchao Li
    Chuanxin Yang
    Chen Jin
    Xinyu Huang
    BMC Gastroenterology, 23
  • [47] Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial
    Shin, Dong Woo
    Lee, Jong-chan
    Kim, Jaihwan
    Yoon, Yoo-Seok
    Han, Ho-Seong
    Kim, Haeryoung
    Hwang, Jin-Hyeok
    PANCREATOLOGY, 2021, 21 (04) : 796 - 804
  • [48] Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer
    Deng, Ting
    Pan, Hong
    Han, Rubing
    Huang, Dingzhi
    Li, Hongli
    Zhou, Likun
    Wang, Xia
    Bai, Ming
    Li, Xiang
    Liu, Rui
    Ge, Shaohua
    Ning, Tao
    Zhang, Le
    Ba, Yi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 7 (12): : 5041 - 5049
  • [49] Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
    Guo, Zhongyi
    Wang, Feng
    Di, Yang
    Yao, Lie
    Yu, Xinzhe
    Fu, Deliang
    Li, Ji
    Jin, Chen
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 : 4869 - 4880
  • [50] EXPRESSION OF HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (HENT1) IS A NOVEL PROGNOSIC MARKER IN ADVANCED BLADDER CANCER PATIENTS WITH GEMCITABINE-BASED CHEMOTHERAPY
    Matsumura, Nagahide
    Nakamura, Yasushi
    Nanpo, Yoshihito
    Kodama, Yoshiki
    Kikkawa, Kazuro
    Ura, Kuniyoshi
    Kusumoto, Hiroki
    Inagaki, Takeshi
    Kohjimoto, Yasuo
    Hara, Isao
    JOURNAL OF UROLOGY, 2011, 185 (04): : E795 - E795
12345